Journal of Gastrointestinal & Digestive System
Open Access

Commentary

Androgen Receptor and Hepatocellular Carcinoma

Tatsuo Kanda^1*, Osamu Yokosuka¹ and Masao Omata^2,3

¹Department of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan

²Yamanashi Hospitals (Central and Kita) Organization, 1-1-1 Fujimi, Kofu-shi, Yamanashi (400-8506), Japan

³University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo (113-8655), Japan

*Corresponding Author:

Tatsuo Kanda
Associate Professor, Department of Gastroenterology and Nephrology
Chiba University, Graduate School of Medicine
1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan
Tel: +81-43-226 2086
Fax: +81-432262088
E-mail: kanda2t@yahoo.co.jp

Received date: April 22, 2013; Accepted date: June 06, 2013; Published date: June 08, 2013

Citation: Kanda T, Yokosuka O, Omata M (2013) Androgen Receptor and Hepatocellular Carcinoma. J Gastroint Dig Syst S12:012. doi: 10.4172/2161-069X.S12-012

Copyright: © 2013 Kanda T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

The androgen receptor (AR) exists in normal liver as well as in human hepatocellular carcinoma (HCC) tissues. Recent studies revealed that AR plays an important role in hepatitis B viral as well as hepatitis C viral hepatocarcinogenesis. The targeting of AR might be developed as a new therapeutic option against HCC. This article provides information regarding the association between AR and HCC.

Keywords